Celcuity Inc. (NASDAQ:CELC) Given Average Rating of "Buy" by Analysts

Celcuity Inc. (NASDAQ:CELC - Get Free Report) has received an average rating of "Buy" from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $29.17.

Several research firms recently weighed in on CELC. Lifesci Capital initiated coverage on Celcuity in a report on Monday, August 26th. They issued an "outperform" rating and a $27.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $27.00 price target on shares of Celcuity in a report on Friday, November 15th. Stifel Nicolaus lifted their price objective on shares of Celcuity from $39.00 to $42.00 and gave the company a "buy" rating in a report on Monday, October 7th. Finally, Needham & Company LLC restated a "buy" rating and set a $23.00 target price on shares of Celcuity in a report on Friday, November 15th.

Institutional Investors Weigh In On Celcuity

Institutional investors have recently bought and sold shares of the company. nVerses Capital LLC purchased a new stake in shares of Celcuity during the 3rd quarter valued at $33,000. Prospera Private Wealth LLC acquired a new position in Celcuity during the 3rd quarter valued at about $35,000. Values First Advisors Inc. acquired a new stake in Celcuity in the third quarter worth about $86,000. Quest Partners LLC boosted its holdings in Celcuity by 31.3% in the second quarter. Quest Partners LLC now owns 5,788 shares of the company's stock worth $95,000 after acquiring an additional 1,379 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Celcuity during the third quarter worth about $119,000. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Trading Up 3.8 %

NASDAQ:CELC traded up $0.46 during midday trading on Friday, hitting $12.46. The stock had a trading volume of 1,207,069 shares, compared to its average volume of 281,445. Celcuity has a one year low of $11.51 and a one year high of $22.19. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. The stock has a 50-day moving average of $14.14 and a 200 day moving average of $15.40. The company has a market capitalization of $462.64 million, a price-to-earnings ratio of -4.77 and a beta of 0.74.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.